[ORGANIZATION]
Vertex Pharmaceuticals
Featured in 5 tracked stories · first seen
Situations
Sionna Therapeutics cystic fibrosis drug trial failure
2 clusters · 4 sources · last updated
Latest: Vertex Pharmaceuticals maintains cystic fibrosis market lead after Sionna Therapeutics trial failure
Sionna Therapeutics discontinued its experimental cystic fibrosis drug, SION-719, after a mid-stage clinical trial failed to show meaningful benefits. The trial, which tested the drug as an adjunctive treatment alongside
Vertex Pharmaceuticals acquisition of Crinetics
2 clusters · 2 sources · last updated
Latest: Vertex Pharmaceuticals lifts revenue outlook on strong cystic fibrosis drug sales
In early July 2026, Vertex Pharmaceuticals announced a $10 billion deal to acquire Crinetics, signaling a major expansion of its drug pipeline. By early August, Vertex reported a stronger-than-expected second‑quarter per
Also covered in
-
Biotech sector updates: Lineage Cell and Latigo Biotherapeutics
[BUSINESS] · 2 sources ·
-
Sionna Therapeutics and Vectus Biosystems target orphan lung disease markets
[BUSINESS] · 2 sources ·